Clin2
NCT06801249Possibly a fitRecruiting

Metyrapone for heart risk in adrenal tumors with Cushing's

Adrenal IncidentalomasCushing Syndrome

Part of Hormones & metabolism clinical trials.

This trial tests if a drug called Metyrapone can lower heart risks in people who have adrenal nodules (noncancerous growths on the adrenal glands) and a mild form of Cushing's syndrome that doesn't cause obvious physical signs. You'll be given the drug and monitored to see if it helps control blood pressure and other heart risk factors.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
50 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have one or more adrenal nodules on a CT scan with thickening of the adrenal glands.
  • You have a mild form of Cushing's syndrome (confirmed by specific hormone tests) without visible signs like weight gain or bruising.
  • You have high blood pressure (140/90 or higher) or take medication for it.
  • You cannot have surgery to remove the nodules.
  • Your blood pressure is between 110/70 and under 130/85 after 6-10 months on a stable dose of blood pressure medication.
  • You are not pregnant, not breastfeeding, and if you could become pregnant, you use double barrier contraception (like condom plus diaphragm).
  • You have not used steroid medications in the last year.
  • You do not have serious liver problems, untreated thyroid issues, or other conditions that would interfere with the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07247162Not yet recruiting· Phase 4
A study on osilodrostat for high blood pressure caused by Cushing's syndrome

This trial tests whether osilodrostat can lower blood pressure in people with Cushing's syndrome whose high blood pressure is not well controlled by their current medications. The drug works by reducing the production of the stress hormone cortisol, which is abnormally high in Cushing's syndrome.

NCT06801340Recruiting
Understanding metabolic risks from adrenal tumors using CT scans

This study looks at CT scans of people with adrenal tumors to understand how the tumor might affect your metabolism. It may help doctors learn more about the condition and improve care.

Bologna
NCT07138274Not yet recruiting· Phase 2
Metyrapone study for mild cortisol excess

This study tests if a medication called metyrapone can help people with mild autonomous cortisol secretion (MACS), a condition where your body makes too much cortisol. It looks at whether the drug improves related health problems like high blood pressure, diabetes, or bone issues.

NCT07268222Recruiting· Phase 4
Comparing two drugs for metabolic autonomous cortisol secretion

This trial tests whether metyrapone or osilodrostat works better for people with MACS, a condition where the adrenal glands produce too much cortisol on their own. The goal is to help you and your doctor choose the best treatment.

Athens
NCT04529629Recruiting
Tests and tracks treatment for adrenal hormone tumor diseases

This trial studies how adrenal hormone tumor diseases should be diagnosed, treated, and followed over time. It may help people get more precise care and better prediction of outcomes, but it has specific health and medication requirements.

Shanghai, Shanghai Municipality
NCT07605156Recruiting
New imaging scan for rare adrenal hormone tumors

This study tests a special imaging scan (PET/CT) to help doctors identify adrenal tumors that produce too much of two hormones: aldosterone and cortisol. If you have both hormone imbalances confirmed by blood tests and are planning surgery to remove your adrenal gland, this scan may help your doctors see exactly where the tumor is.

Beijing

Hear when a new Cushing Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.